Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 6/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA4 | P22748 | 1/20 | 0.59 |
| ▸ | CA6 | P23280 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | TPMT | P51580 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9364577 | 0.91 | CYP1A2 (0.96) | CYP1A2CYP3A4CYP2C9CYP2C19TSHR | |
| Veratric Acid Methyl Ester SCHEMBL2050732 | 0.89 | MAPT (0.86) | CYP1A2CYP3A4CYP2C9CYP2C19TSHR | |
| Veratric Acid Methyl Ester SCHEMBL29573244 | 0.89 | MAPT (0.86) | CYP1A2CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL1493250 | 0.89 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL10421110 | 0.86 | SLC22A6 (0.80) | CYP1A2CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL3468486 | 0.85 | LMNA (0.63) | CYP1A2CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL2269669 | 0.85 | ALDH1A1 (0.81) | CYP1A2CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL1333620 | 0.84 | CYP1A2 (0.81) | CYP1A2CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL6872165 | 0.84 | TSHR (0.81) | CYP1A2CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL4818731 | 0.84 | ALDH1A1 (1.00) | CYP1A2CYP3A4CYP2C9CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176995-A1 | Soluble fullerene derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA INSTITUTE OF TECHNOLOGY (JP) | 2009-07-09 | — | — | US | disclosed |
| US-20090176995-A1 | Soluble fullerene derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA INSTITUTE OF TECHNOLOGY (JP) | 2009-07-09 | — | — | US | disclosed |
| US-20090176995-A1 | Soluble fullerene derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA INSTITUTE OF TECHNOLOGY (JP) | 2009-07-09 | — | — | US | disclosed |
| US-6812231-B2 | INHIBITING ACTIVATED BLOOD-COAGULATION FACTOR X | AJINOMOTO CO., INC. (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20020107290-A1 | Benzamidine derivative | AJINOMOTO CO., INC. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-6410538-B2 | ANTICOAGULANT OR AN AGENT FOR TREATING OR PREVENTING THROMBI OR EMBOLI | AJINOMOTO CO., INC. (JP) | 2002-06-25 | — | — | US | disclosed |
| US-20010056123-A1 | Anticoagulant or an agent for treating or preventing thrombi or emboli | AJINOMOTO CO., INC (JP) | 2001-12-27 | — | — | US | disclosed |
| EP-1086946-A1 | BENZAMIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2001-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176995-A1 | Soluble fullerene derivatives | SOD1, EPCAM, NDUFV2 | CYP1A2 528/4885CYP3A4 878/4885CYP2C9 1161/4885 |
| US-20020107290-A1 | Benzamidine derivative | SERPINE1, SERPINC1, TFPI | CYP1A2 776/4885CYP3A4 299/4885CYP2C9 203/4885 |
| US-20010056123-A1 | Anticoagulant or an agent for treating or preventing thrombi or emboli | SERPINC1, SERPINE1, F2 | CYP1A2 881/4885CYP3A4 746/4885CYP2C9 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.